Qube Research & Technologies (QRT)’s Sarepta Therapeutics SRPT Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11M	Buy	+609,796	New	+$11.5M	0.01%	1238
2025 Q3	–	Sell	-1,598,472	Closed	-$27.3M	–	3932
2025 Q2	$27.3M	Buy	1,598,472 +1,566,564	+4,910%	+$66.8M	0.03%	717
2025 Q1	$2.04M	Buy	+31,908	New	+$3.36M	﹤0.01%	1952
2024 Q2	–	Sell	-11,869	Closed	-$1.54M	–	4674
2024 Q1	$1.54M	Buy	11,869 +10,650	+874%	+$1.3M	﹤0.01%	1894
2023 Q4	$118K	Buy	1,219 +946	+347%	+$90.7K	﹤0.01%	3046
2023 Q3	$33.1K	Buy	+273	New	+$30.9K	﹤0.01%	2991
2022 Q4	–	Sell	-12,728	Closed	-$1.41M	–	2966
2022 Q3	$1.41M	Buy	+12,728	New	+$1.28M	0.01%	1067
2021 Q2	–	Sell	-31,662	Closed	-$2.36M	–	2772
2021 Q1	$2.36M	Sell	31,662 -4,063	-11%	-$375K	0.04%	576
2020 Q4	$6.09M	Buy	+35,725	New	+$5.29M	0.09%	265
2020 Q3	–	Sell	-23,926	Closed	-$3.84M	–	2081
2020 Q2	$3.84M	Buy	+23,926	New	+$3.26M	0.06%	441

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Qube Research & Technologies (QRT)'s SRPT Position: Q2 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 609,796 shares worth $11M. The stake represents 0.01% of the portfolio and ranks #1238 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in SRPT as recently as Q2 2025.

Qube Research & Technologies (QRT) first reported a position in SRPT in Q2 2020 and has held it in 10 quarters since. The position peaked at $27.3M in Q2 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Qube Research & Technologies (QRT) held 609,796 shares of Sarepta Therapeutics worth $11M as of Q2 2026.
Sarepta Therapeutics was a new Qube Research & Technologies (QRT) position in Q2 2026.
Sarepta Therapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1238 holding.
Qube Research & Technologies (QRT) first reported a position in Sarepta Therapeutics in Q2 2020 and has held it in 10 quarters since.
Qube Research & Technologies (QRT)'s Sarepta Therapeutics position peaked at $27.3M in Q2 2025.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.